pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PTCPTC INC.

$PTC153.52+0.71%
Boston, MA, USupdated 5h ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
2
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 3: 1Marketed: 2
1Phase 32Marketed
Marketed
eladocagene exuparvovec
Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
Marketed
sepiapterin
Hyperphenylalaninemia
Phase 3
vatiquinone
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic A…
NAD(P)H dehydrogenase [quinone] 1

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Jul 29, 2026
earnings
$PTC153.52+0.71%
23d ago
PTC INC. earnings
PTC INC.
→
view all catalysts →

Active trials

  • phase3Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)not yet recruitingn=120
  • phase2A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participantsactive not recruitingn=13
  • phase3A Long-Term Safety Study of PTC923 in Participants With Phenylketonuriaactive not recruitingn=200
  • phase3A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxiacompletedn=146
  • phase3A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsyterminatedn=68
  • phase3A Study of Sepiapterin in Participants With Phenylketonuria (PKU)recruitingn=56
  • phase3Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophycompletedn=360
  • phase3Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)completedn=270
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 16, 26SELLLathan Corinna· director675 sh @ $157.24−$106K↗
  • Mar 3, 26SELLVON STAATS AARON C· EVP, Chief Legal Officer2,639 sh @ $160.00−$422K↗
routine RSU / option mechanics (2)
  • Mar 15, 26option exercisePham Trac · director1,181 sh
  • Mar 15, 26option exercisePham Trac · director1,181 sh
🐶 Hiring Signal
No open roles indexed yet — view PTC INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$PTC
SEC CIK
0000857005
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 4m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?